Hyperphosphatemic Familial Tumoral Calcinosis.
Kaszycki M, Villalpando B, Hickson L, Rao S, Wierenga K, Garner H, Sokumbi O, Tolaymat L.
South Med J. 2024 Dec;117(12):705-708. doi: 10.14423/SMJ.0000000000001759.
Hyperphosphatemic familial tumoral calcinosis in a dancer.
Li WX, Stanek J.
PM R. 2023 May;15(5):685-687. doi: 10.1002/pmrj.12818. Epub 2022 Jun 15.
Familial tumoral calcinosis.
Alkhatib A, Burton LE, Carachi R.
Scott Med J. 2014 Nov;59(4):e17-20. doi: 10.1177/0036933014557416. Epub 2014 Oct 27.
Familial tumoral calcinosis: a valuable vehicle for discovery.
Moe OW.
Nephrol Dial Transplant. 2014 Dec;29(12):2155-7. doi: 10.1093/ndt/gfu270. Epub 2014 Aug 21.
Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis.
Chefetz I, Sprecher E.
Biochim Biophys Acta. 2009 Sep;1792(9):847-52. doi: 10.1016/j.bbadis.2008.10.008. Epub 2008 Oct 25.
Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
Folsom LJ, Imel EA.
Curr Osteoporos Rep. 2015 Apr;13(2):78-87. doi: 10.1007/s11914-015-0254-3.
Tumoral calcinosis: new insights for the rheumatologist into a familial crystal deposition disease.
Sprecher E.
Curr Rheumatol Rep. 2007 Jun;9(3):237-42. doi: 10.1007/s11926-007-0038-6.
Familial tumoral calcinosis: a rare autosomal recessive disease.
Moran H, Malvar M, Yuksel S, Bleich D.
BMJ Case Rep. 2024 Oct 11;17(10):e259455. doi: 10.1136/bcr-2023-259455.
Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.
Chakhtoura M, Ramnitz MS, Khoury N, Nemer G, Shabb N, Abchee A, Berberi A, Hourani M, Collins M, Ichikawa S, El Hajj Fuleihan G.
Osteoporos Int. 2018 Sep;29(9):1987-2009. doi: 10.1007/s00198-018-4574-x. Epub 2018 Jun 20.
Hyperphosphataemic tumoral calcinosis.
Tiwari V, Goyal A, Nagar M, Santoshi JA.
Lancet. 2019 Jan 12;393(10167):168. doi: 10.1016/S0140-6736(18)33045-9.
